Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
ImExHS Limited ( (AU:IME) ) has shared an announcement.
ImExHS Limited has launched an AI-native, agentic platform for radiology by embedding five proprietary AI agents across its Aquila+ RIS/PACS workflow, from appointment scheduling to final report delivery. Two agents are already live for clients, one is in final testing and two are under active development, positioning Aquila+ as a fully integrated, AI-driven system rather than a collection of add-on tools.
The agents are designed to automate scheduling, triage, case distribution, SLA monitoring and in-report support, aiming to cut staffing needs, reduce patient wait times and increase radiologist productivity without proportional headcount growth. Management says this agentic architecture should deepen customer reliance on Aquila+, raise switching costs and create cross-sell opportunities, strengthening the company’s competitive moat and marking a strategic pivot to an AI-native radiology workflow platform.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
More about ImExHS Limited
ImExHS Limited is an Australian-listed medical technology company specialising in radiology information systems and picture archiving and communication systems. Its next-generation Aquila+ RIS/PACS platform targets diagnostic imaging providers, focusing on workflow automation and AI-driven tools to improve efficiency, clinical safety and scalability in radiology services.
Average Trading Volume: 28,587
Technical Sentiment Signal: Sell
Current Market Cap: A$20.82M
See more insights into IME stock on TipRanks’ Stock Analysis page.